Adtalem Global Education (NYSE:CVSA) Now Covered by Analysts at Truist Financial

Key Points

• Truist initiated coverage with a Buy rating and a $130 price target (≈18.5% upside), while MarketBeat shows a consensus Buy rating and an average price target of $150.
• Insider buying: Director Michael W. Malafronte purchased 8,890 shares at $100.94 (a 53.86% increase in his stake), and insiders bought 37,236 shares worth $3.75M over the last 90 days (insiders own 2.5%).
• Latest quarter: EPS of $2.43 and revenue of $503.39M; the stock trades at a P/E of 16.11 with a market cap of $3.78B and a 12‑month range of $86.97–$156.26.

Analysts at Truist Financial initiated coverage on shares of Adtalem Global Education (NYSE:CVSA - Get Free Report) in a note issued to investors on Tuesday. The brokerage set a "buy" rating and a $130.00 price target on the stock. Truist Financial's price target indicates a potential upside of 18.53% from the stock's previous close.

A number of other analysts have also weighed in on CVSA. Zacks Research raised shares of Adtalem Global Education from a "hold" rating to a "strong-buy" rating in a research note on Tuesday, February 24th. Barrington Research reaffirmed an "outperform" rating and issued a $170.00 price target on shares of Adtalem Global Education in a research report on Monday, March 2nd. Finally, Weiss Ratings began coverage on shares of Adtalem Global Education in a research note on Wednesday, February 25th. They set a "hold (c+)" rating on the stock. One research analyst has rated the stock with a Strong Buy rating, two have given a Buy rating and one has given a Hold rating to the stock. According to data from MarketBeat, the company presently has a consensus rating of "Buy" and an average price target of $150.00.

Adtalem Global Education Stock Up 3.0%

Shares of NYSE CVSA opened at $109.68 on Tuesday. The company has a debt-to-equity ratio of 0.37, a current ratio of 0.68 and a quick ratio of 0.68. The firm has a market cap of $3.78 billion, a price-to-earnings ratio of 16.11, a PEG ratio of 0.90 and a beta of 0.72. Adtalem Global Education has a twelve month low of $86.97 and a twelve month high of $156.26.

Adtalem Global Education (NYSE:CVSA - Get Free Report) last posted its quarterly earnings results on Wednesday, January 28th. The company reported $2.43 earnings per share (EPS) for the quarter. The business had revenue of $503.39 million for the quarter. Adtalem Global Education had a return on equity of 20.24% and a net margin of 13.41%.

Insiders Place Their Bets

In related news, Director Michael W. Malafronte acquired 8,890 shares of the company's stock in a transaction that occurred on Wednesday, March 11th. The shares were bought at an average price of $100.94 per share, with a total value of $897,356.60. Following the completion of the transaction, the director directly owned 25,395 shares in the company, valued at $2,563,371.30. This trade represents a 53.86% increase in their ownership of the stock. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Insiders bought a total of 37,236 shares of company stock worth $3,752,866 over the last 90 days. 2.50% of the stock is owned by company insiders.

Adtalem Global Education Company Profile

Adtalem Global Education NYSE: CVSA is a provider of higher education and workforce solutions focused primarily on programs that prepare students for professional careers in healthcare, medicine, veterinary medicine and related fields. The company operates campus-based and online degree programs, continuing professional education, clinical training and exam-preparation offerings designed to support students seeking licensure and employment in regulated professions.

Adtalem’s portfolio includes institution brands that deliver undergraduate, graduate and professional training across nursing, medicine, veterinary medicine and allied health disciplines.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.